Last updated: July 14, 2026
ARAGON PHARMACEUTICALS v. MSN PHARMACEUTICALS (2:26-cv-07798) Litigation Summary and Patent Case Analysis
Executive summary
ARAGON PHARMACEUTICALS, INC. v. MSN PHARMACEUTICALS INC., docket 2:26-cv-07798, is an active federal patent case filed in 2026. No public, citable case-specific record (claims asserted, patent numbers, Paragraph IV status, asserted Orange Book patents, or settlement posture) is available in the information provided in this request. Without those core filings, a reliable litigation summary and patent estate analysis cannot be produced.
What does the docket 2:26-cv-07798 cover and what patents are at issue?
A litigation summary for this docket requires the complaint and/or operative scheduling order identifying:
- the asserted U.S. patents (publication/patent numbers),
- the FDA product and NDA/ANDA/BLA referenced in the infringement theory,
- the legal bases (typically 35 U.S.C. § 271(e)(2) for Hatch-Waxman),
- and the specific drug claims and dosage forms at issue.
That information is not contained in the request.
Which court and what procedural posture
A complete litigation posture requires at least one of:
- the filing court (district and division),
- the case caption with plaintiffs and defendants (including any subsidiary entities),
- the date of complaint, venue judge, and assigned magistrate,
- and the latest docket entry (e.g., motion to dismiss, claim construction, preliminary injunction, summary judgment).
No docket metadata beyond the case number is provided.
Is this a Paragraph IV (Hatch-Waxman) or patent-only dispute
The distinction drives the entire analysis framework (Orange Book, FDA “Orange Book” listing(s), 30-month stay, potential settlement agreement triggers). The request does not state whether the case is tied to an ANDA Paragraph IV notice.
What patent litigation affects MSN Pharmaceuticals in 2:26-cv-07798?
A litigation impact analysis normally maps:
- which MSN product(s) are accused,
- whether there is an agreed carve-out design-around,
- whether any patents were dismissed,
- whether claim construction narrowed the asserted scope,
- and what the court’s rulings mean for generic launch risk.
Those outcomes depend on docket orders and claim charts that are not supplied here.
What claims were asserted and what infringement theory
Hard data needed:
- asserted claims per patent,
- alleged infringement by the proposed ANDA/Biologics product,
- and whether theories include inducement or willful infringement.
No asserted claims or patents are provided.
What remedies are sought
A true “litigation analysis” must state whether the plaintiff seeks:
- 35 U.S.C. § 271(e)(4)(B) remedies,
- injunction against FDA approval,
- damages for commercial manufacture,
- attorneys’ fees (exceptional case),
- and/or a declaration of non-infringement or invalidity.
No remedy details are provided.
How strong is the patent estate in ARAGON v. MSN for the accused drug?
Patent estate strength analysis requires:
- the full list of Orange Book patents tied to the reference listed drug,
- each patent’s expiration date (and any PTA/PTE),
- exclusivity protections (e.g., NCE, orphan, 5-year, data exclusivity),
- and whether any patents are design patents, method-of-use, formulation, or manufacturing process.
No list of patents, expiration schedule, or exclusivity timing is available from the request.
Expiration and exclusivity timeline
To answer “When does exclusivity end?” and “When do patents lose exclusivity?” you must have:
- patent numbers and grant dates,
- expiration dates including PTA/PTE,
- and any pediatric exclusivity or statutory extensions.
No such data is provided.
What formulation, method-of-use, or manufacturing patents are protected?
This section requires:
- patent claim categories (composition/formulation vs method-of-use vs manufacturing),
- key claim language,
- and mapping of claims to the accused dosage form and manufacturing steps.
No patent numbers or claims are provided.
What is the Orange Book status of ARAGON’s drug in this case?
Orange Book status analysis requires:
- the listed drug name,
- the NDA number,
- and the Orange Book patent list with expiration dates.
No Orange Book data is provided.
When could MSN launch if the case resolves or patents expire?
A launch risk model requires:
- whether there is a 30-month stay (Paragraph IV),
- whether any settlement triggers early work or “carve-out” dates,
- the effective dismissal/invalidity outcomes,
- and the earliest enforceable patent expiration.
None of these facts are provided.
Were Paragraph IV challenges filed and what settlement dates apply?
A proper settlement analysis requires:
- notice date (FDA Paragraph IV filing date),
- settlement agreement date,
- any consent judgments,
- and the “triggering event” framework used in Hatch-Waxman settlements.
No settlement details are provided.
How does ARAGON’s case compare with other generic challenges involving similar patents?
This needs comparison anchors:
- whether other defendants are in parallel dockets,
- whether courts have already construed key patents,
- and whether prior litigations produced consistent non-infringement/invalidity holdings.
No parallel cases or patent numbers are provided.
Key Takeaways
- The request identifies only the docket number 2:26-cv-07798 and the parties (ARAGON PHARMACEUTICALS, INC. and MSN PHARMACEUTICALS INC.).
- A litigation summary and patent estate analysis require asserted patent numbers, FDA product/NDA/ANDA linkage, and docket outcomes.
- Those core facts are not included in the provided input; a complete and accurate analysis cannot be produced under the operating constraints.
FAQs
- What is the court location and judge for docket 2:26-cv-07798?
- Which patents did ARAGON assert against MSN in 2:26-cv-07798?
- Does 2:26-cv-07798 involve a Paragraph IV ANDA notice and a 30-month stay?
- What are the earliest potential launch dates if the asserted patents expire during the case?
- Did ARAGON and MSN reach any settlement agreement or consent judgment?
References (APA)
No sources were cited because no docket, complaint, patent, Orange Book, or FDA linkage information was provided in the request.
